Plasma Levels of Soluble AβPPβ as a Biomarker for Alzheimer's Disease with Dementia

被引：1

作者：

Alexopoulos, Panagiotis ^{[1
,2
]}

Thierjung, Nathalie ^{[1
]}

Economou, Polychronis ^{[3
]}

Werle, Lukas ^{[1
,4
]}

Buhl, Felix ^{[1
]}

Kagerbauer, Simone ^{[5
]}

Papanastasiou, Anastasios D. ^{[6
]}

Grimmer, Timo ^{[1
]}

Gourzis, Philippos ^{[2
]}

Berthele, Achim ^{[7
]}

Hemmer, Bernhard ^{[7
,8
]}

Kuebler, Hubert ^{[9
]}

Martin, Jan ^{[5
]}

Politis, Antonios ^{[10
,11
]}

Perneczky, Robert ^{[8
,12
,13
,14
]}

机构：

[1] Tech Univ Munich, Dept Psychiat & Psychotherapy, Klinikum Rechts Isar, Munich, Germany

[2] Univ Patras, Univ Hosp Rion, Dept Psychiat, Patras, Greece

[3] Univ Patras, Dept Civil Engn Stat, Patras, Greece

[4] Max Planck Inst Psychiat, Munich, Germany

[5] Tech Univ Munich, Dept Anaesthesiol, Klinikum Rechts Isar, Munich, Germany

[6] Univ Patras, Mol Oncol Lab, Div Oncol, Univ Hosp Patras, Patras, Greece

[7] Tech Univ Munich, Dept Neurol, Klinikum Rechts Isar, Munich, Germany

[8] Munich Cluster Syst Neurol SyNergy, Munich, Germany

[9] Tech Univ Munich, Dept Urol, Klinikum Rechts Isar, Munich, Germany

[10] Univ Athens, Dept Psychiat 1, Eginit Hosp, Athens, Greece

[11] Johns Hopkins Med Sch, Dept Psychiat, Div Geriatr Psychiat & Neuropsychiat, Baltimore, MD USA

[12] Ludwig Maximilians Univ Munchen, Dept Psychiat & Psychotherapy, Munich, Germany

[13] Imperial Coll Sci Technol & Med, Ageing Epidemiol AGE Res Unit, Sch Publ Hlth, Fac Med, London, England

[14] German Ctr Neurodegenerat Dis DZNE Munich, Munich, Germany

来源：

JOURNAL OF ALZHEIMERS DISEASE | 2019年 / 69卷 / 01期

关键词：

Biomarker candidate; NIA-AA research framework diagnostic criteria; soluble amyloid-beta protein precursor beta; CEREBROSPINAL-FLUID BIOMARKERS; AMYLOID PRECURSOR PROTEINS; MILD COGNITIVE IMPAIRMENT; BACE1; ACTIVITY; CSF; BETA-AMYLOID((1-42)); METABOLISM; CLEARANCE; DECLINE; MARKERS;

D O I：

10.3233/JAD-181088

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Cost- and time-effective markers of Alzheimer's disease (AD), reliable and feasible at the population level are urgently needed. Soluble amyloid-beta protein precursor beta (sA beta PP beta) in plasma has attracted scientific attention as a potential AD biomarker candidate. Here we report that plasma sA beta PP beta levels in patients with AD dementia and typical for AD cerebrospinal fluid (CSF) biomarker profiles (N = 33) are significantly lower (p < 0.01) than those of cognitively healthy elderly individuals without AD (N = 39), while CSF sA beta PP beta levels did not differ between the studied groups. This provides further evidence for the potential of sA beta PP beta in plasma as an AD biomarker candidate.

引用

页码：83 / 90

页数：8

共 50 条

[41] Plasma Biomarkers in the Distinction of Alzheimer's Disease and Frontotemporal Dementia
Gomez-Tortosa, Estrella
Aguero-Rabes, Pablo
Ruiz-Gonzalez, Alicia
Wagner-Reguero, Sonia
Tellez, Raquel
Mahillo, Ignacio
Ruiz-Calvo, Andrea
Sainz, Maria Jose
Nystrom, Anna Lena
del Ser, Teodoro
Sanchez-Juan, Pascual
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (03)
[42] Elevated plasma homocysteine levels: Risk factor or risk marker for the development of dementia and Alzheimer's disease?
Seshadri, Sudha
JOURNAL OF ALZHEIMERS DISEASE, 2006, 9 (04) : 393 - 398
[43] REPS1 as a Potential Biomarker in Alzheimer's Disease and Vascular Dementia
Luo, Jiefeng
Chen, Liechun
Huang, Xiaohua
Xie, Jieqiong
Zou, Chun
Pan, Mika
Mo, Jingjia
Zou, Donghua
FRONTIERS IN AGING NEUROSCIENCE, 2022, 14
[44] OxLDL plasma levels in patients with Alzheimer's disease
Grossi, Marina Felipe
Gracas Carvalho, Maria das
Silveira, Josionne Nicacio
Goncalves, Gisele Santos
Gomes, Karina Braga
Bicalho, Maria Aparecida
Oliveira Silva, Ieda de Fatima
ARQUIVOS DE NEURO-PSIQUIATRIA, 2018, 76 (04) : 241 - 246
[45] Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy
Chouliaras, Leonidas
Thomas, Alan
Malpetti, Maura
Donaghy, Paul
Kane, Joseph
Mak, Elijah
Savulich, George
Prats-Sedano, Maria A.
Heslegrave, Amanda J.
Zetterberg, Henrik
Su, Li
Rowe, James Benedict
O'Brien, John Tiernan
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, : 651 - 658
[46] Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia
Willemse, Eline A. J.
Sieben, Anne
Somers, Charisse
Vermeiren, Yannick
De Roeck, Naomi
Timmers, Maarten
Van Broeckhoven, Christine
De Vil, Bart
Cras, Patrick
Deyn, Peter P. De
Martin, Jean -Jacques
Teunissen, Charlotte E.
Engelborghs, Sebastiaan
Bjerke, Maria
NEUROBIOLOGY OF AGING, 2021, 108 : 99 - 109
[47] Cognitive Functions as Predictors of Alzheimer's Disease Biomarker Status in the European Prevention of Alzheimer's Dementia Cohort
Terrera, Graciela Muniz
Harrison, John E.
Ritchie, Craig W.
Ritchie, Karen
JOURNAL OF ALZHEIMERS DISEASE, 2020, 74 (04) : 1203 - 1210
[48] An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia
Berlyand, Yosef
Weintraub, Daniel
Xie, Sharon X.
Mellis, Ian A.
Doshi, Jimit
Rick, Jacqueline
McBride, Jennifer
Davatzikos, Christos
Shaw, Leslie M.
Hurtig, Howard
Trojanowski, John Q.
Chen-Plotkin, Alice S.
PLOS ONE, 2016, 11 (01):
[49] Molecular Status of Plasma Fibronectin as an Additional Biomarker for Assessment of Alzheimer's Dementia Risk
Lemanska-Perek, Anna
Leszek, Jerzy
Krzyzanowska-Golab, Dorota
Radzik, Jacek
Katnik-Prastowska, Iwona
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2009, 28 (04) : 338 - 342
[50] Cerebrospinal fluid levels of soluble intercellular adhesion molecule-1 in Alzheimer's disease and other dementia disorders
De Jong, D
Kremer, B
Jansen, R
Schoonderwaldt, H
De Waal, R
Verbeek, M
Van Swieten, J
NEUROBIOLOGY OF AGING, 2002, 23 (01) : S381 - S381

← 1 2 3 4 5 →